NCT00614978 - Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Metastatic Breast CancerBrain MetastasesHER2 Positive

Interventions

DRUG

lapatinib and temozolomide

Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.

Trial Locations (1)

1000

Jules Bordet Institute, Brussels